Call 1 (888) 460-6556 to speak with a counselor.

Journal of Medical Economics, Ahead of Print. (Source: Journal of Medical Economics)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

Call 1 (888) 460-6556 to speak with a counselor.

The product license of buprenorphine/naloxone for opioid substitution therapy indicates reducing methadone concentrations to 30 mg or less per day for a minimum of 1 week before transferring patients to buprenorphine and no sooner than 24 hours after the last methadone dose, because of the risk of precipitated withdrawal and a corresponding high risk of relapse to opioid use. There are few studies describing high-dose methadone transfers. This retrospective case review assessed the feasibility of transferring patients on methadone doses above 30 mg/day to buprenorphine or buprenorphine/naloxone in the inpatient setting. (Source: Journal of Substance Abuse Treatment)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

Factors associated with willingness to take extended release naltrexone among injection drug users.

May 2, 2015

CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional […]

Read the full article →

Factors associated with willingness to take extended release naltrexone among injection drug users

May 2, 2015

Conclusions: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional […]

Read the full article →

Starting Suboxone Therapy in the ED Benefits Opioid-Dependent Patients (FREE)

April 28, 2015

By Daniel J. Pallin, MD, MPH Opioid-dependent individuals visiting the emergency department are much more likely to participate in addiction treatment when buprenorphine/naloxone therapy is started during the visit, a JAMA study finds.Investigators randomized some 330 adult patients reporting opioid dependence to one of … (Source: Physician’s First Watch current issue) MedWorm Sponsor Message: Directory […]

Read the full article →

Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients

April 20, 2015

The high prevalence of interrelated problems with opioid use disorder, injection drug use (IDU), and HIV/AIDS in Malaysia has led to the scale-up of public health approaches, including opioid agonist maintenance treatment with buprenorphine or methadone. Malaysia has more than 300,000 registered people who use drugs (PWUD)-approximately 1.1% of its population of about 30 million-and […]

Read the full article →

Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic

April 15, 2015

Opinion statement Prescription opioid misuse has been a significant epidemic during the past decade. Formulations of prescription opioids with different mechanisms of abuse-deterrence have been developed or are currently under development. Given that these medications are substantially more difficult to use in an illicit fashion and minimize the potential for euphoria and/or create an aversive […]

Read the full article →

Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003

April 9, 2015

Opiate withdrawal scales were developed to examine the patient’s physical dependence and physiological readiness prior to methadone or buprenorphine induction, and to compare treatments for withdrawal (Wesson and Ling, 2003). The Clinical Opiate Withdrawal Scale (COWS; Wesson and Ling, 2003) is a common measure used to assess withdrawal in clinical trials and practice, and consists […]

Read the full article →

Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients

March 31, 2015

Diversion and abuse of the medications used in opioid maintenance treatment (OMT) methadone (MET), mono-buprenorphine (BUP) and buprenorphine-naloxone (BNX) have been documented in countries around the world, for example in France (Auriacombe, Fatseas, Dubernet, Daulouede, & Tignol, 2004; Nordmann et al., 2012; Obadia, Perrin, Feroni, Vlahov, & Moatti, 2001; Roux et al., 2008a; Roux et […]

Read the full article →

Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.

March 26, 2015

Authors: Sullivan JG, Webster L Abstract PURPOSE: The purpose of this study was to provide a preliminary assessment of the safety, tolerability, symptom control, and acceptability of buprenorphine-naloxone buccal film (BBN) for the maintenance treatment of opioid dependence in patients converted from buprenorphine-naloxone sublingual tablet or film (SLBN), as well as to determine the conversion […]

Read the full article →